Curis (NASDAQ:CRIS) Share Price Crosses Above 200-Day Moving Average of $10.73

Curis, Inc. (NASDAQ:CRIS) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.73 and traded as high as $15.27. Curis shares last traded at $15.27, with a volume of 22,370 shares traded.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on shares of Curis from $51.00 to $26.00 and set a “buy” rating for the company in a report on Friday, February 9th.

Curis Price Performance

The business’s fifty day moving average is $11.26 and its 200-day moving average is $10.73. The firm has a market cap of $89.94 million, a PE ratio of -1.70 and a beta of 3.72.

Curis (NASDAQ:CRIS) last issued its earnings results on Thursday, February 8th. The biotechnology company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.91) by ($0.12). The business had revenue of $2.70 million for the quarter, compared to the consensus estimate of $2.95 million. Curis had a negative return on equity of 169.22% and a negative net margin of 473.04%. During the same quarter in the prior year, the business earned ($2.40) EPS. Analysts forecast that Curis, Inc. will post -5.92 EPS for the current year.

Hedge Funds Weigh In On Curis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd boosted its position in shares of Curis by 40.2% in the first quarter. Dynamic Technology Lab Private Ltd now owns 40,700 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 11,660 shares during the period. LPL Financial LLC boosted its position in shares of Curis by 85.4% in the second quarter. LPL Financial LLC now owns 93,977 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 43,275 shares during the period. Virtu Financial LLC boosted its position in shares of Curis by 235.8% in the second quarter. Virtu Financial LLC now owns 70,848 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 49,748 shares during the period. Two Sigma Investments LP boosted its position in shares of Curis by 175.2% in the first quarter. Two Sigma Investments LP now owns 116,477 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 74,149 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Curis by 56.6% in the first quarter. Bank of America Corp DE now owns 112,227 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 40,583 shares during the period. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.